Comparison of perioperative morbidity in patients with ovarian malignancy undergoing radical cancer surgery with or without prior chemotherapy

被引:0
|
作者
Kathirvel, S
Saxena, A
Trikha, A
Saxena, A
Saxena, R
Ahuja, RK
机构
[1] All India Inst Med Sci, Inst Rotary Canc Hosp, New Delhi, India
[2] All India Inst Med Sci, Dept Anesthesiol, New Delhi, India
[3] All India Inst Med Sci, Dept Cardiol, New Delhi, India
[4] All India Inst Med Sci, Dept Hematol, New Delhi, India
[5] All India Inst Med Sci, Dept Biostat, New Delhi, India
关键词
chemotherapy; ovarian malignancy; perioperative morbidity;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Evaluation was undertaken of the effect of chemotherapeutic drugs on the perioperative morbidity of patients with ovarian malignancy undergoing radical surgery. Twenty patients who had received cytotoxic drugs pre-operatively (group I) were compared with 11 patients in whom radical surgery was the first line of treatment (group IT). Pre and post-operative cardiac, pulmonary, renal, hepatic and coagulation functions were compared in both groups, as well as the critical intra- and post-operative events like cardiac pump failure, respiratory dysfunction, rhythm disturbances, blood loss, etc. Demographic data, ASA status, biochemical and haematological parameters and cardiac ejection fractions were comparable in the two groups but patients in group I had significantly higher left ventricular end diastolic dimensions (P<0.01). A higher number of patients in group I had pre-operative respiratory and coagulation factor abnormalities but critical intra- and post-operative events in both groups were comparable. The surgical time was significantly (P<0.01) longer in group I (5.5+/-2.5 h) as compared to group II (4.5+/-1.5 h). One patient with extensive tumour spread and pre-operatively deranged coagulation profile (group I) died of disseminated intravascular coagulation in the post-operative period. It is concluded that patients with advanced ovarian malignancy, treated with cytotoxic drugs are more likely to have pre-operative cardiac, respiratory and coagulation abnormalities, which should be managed by thorough pre-operative evaluation and intensive intra- and post-operative monitoring.
引用
收藏
页码:175 / 181
页数:7
相关论文
共 50 条
  • [41] Risk of Ovarian Malignancy in Patients Undergoing Surgery for an Adnexal Mass at a High-Volume Cancer Center
    Byrne, Maureen E.
    Spross, Jennifer
    Zivanovic, Oliver
    Gardner, Ginger
    Chi, Dennis
    Roche, Kara Long
    OBSTETRICS AND GYNECOLOGY, 2018, 131 : 18S - 18S
  • [42] Primary debulking surgery versus neo-adjuvant chemotherapy in stage III/IV ovarian cancer: Comparison of perioperative morbidity and survival data in Pakistani women
    Chishti, Uzma
    Aziz, Aliya Begum
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2015, 65 (03) : 306 - 309
  • [43] Perioperative fluid status and surgical outcomes in patients undergoing cytoreductive surgery for advanced epithelial ovarian cancer
    Desale, M. G.
    Tanner, E. J., III
    Sinno, A. K.
    Angarita, A. Africano
    Fader, A. N.
    Stone, R. L.
    Levinson, K. L.
    Bristow, R. E.
    Roche, K. Long
    GYNECOLOGIC ONCOLOGY, 2017, 144 (01) : 61 - 64
  • [44] Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?
    Yoneoka, Yutaka
    Ishikawa, Mitsuya
    Uehara, Takashi
    Shimizu, Hanako
    Uno, Masaya
    Murakami, Takashi
    Kato, Tomoyasu
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 30 (05)
  • [45] Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer
    Tseng, Jill H.
    Cowan, Renee A.
    Afonso, Anoushka M.
    Zhou, Qin
    Iasonos, Alexia
    Ali, Narisha
    Thompson, Errika
    Sonoda, Yukio
    O'Cearbhaill, Roisin E.
    Chi, Dennis S.
    Abu-Rustum, Nadeem R.
    Roche, Kara Long
    GYNECOLOGIC ONCOLOGY, 2018, 151 (02) : 287 - 293
  • [46] Outcomes of elderly patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal cancer peritoneal carcinomatosis
    Klaver, Yvonne L. B.
    Chua, Terence C.
    de Hingh, Ignace H. J. T.
    Morris, David L.
    JOURNAL OF SURGICAL ONCOLOGY, 2012, 105 (02) : 113 - 118
  • [47] Weight loss during neoadjuvant chemotherapy impacts perioperative outcomes in patients undergoing surgery for pancreatic cancer
    Doshi, Sahil
    Abad, John
    Wells, Amy
    Chawla, Akhil
    PANCREATOLOGY, 2023, 23 (08) : 1020 - 1027
  • [48] Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery
    Liu, Ying L.
    Filippova, Olga T.
    Zhou, Qin
    Iasonos, Alexia
    Chi, Dennis S.
    Zivanovic, Oliver
    Sonoda, Yukio
    Gardner, Ginger J.
    Broach, Vance A.
    O'Cearbhaill, Roisin E.
    Konner, Jason A.
    Aghajanian, Carol
    Roche, Kara Long
    Tew, William P.
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2020, 31 (01)
  • [49] A nomogram to predict survival probability of gastric cancer patients undergoing radical surgery and adjuvant chemotherapy
    Ma, Ling
    Chen, Guosheng
    Wang, Deqiang
    Zhang, Kai
    Zhao, Fengjiao
    Tang, Jie
    Zhao, Jianyi
    Roe, Oluf Dimitri
    He, Shaohua
    Liao, Dongcheng
    Gu, Yanhong
    Tao, Min
    Shu, Yongqian
    Li, Wei
    Chen, Xiaofeng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [50] Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy
    Parikh, AA
    Gentner, B
    Wu, TT
    Curley, SA
    Ellis, LM
    Vauthey, JN
    JOURNAL OF GASTROINTESTINAL SURGERY, 2003, 7 (08) : 1082 - 1088